ACTU
ACTUATE THERAPEUTICS, INC.
NASDAQ · Healthcare · Biotechnology · US
$0.37
+5.69%Nov 4, 2026, 13:00 UTC
ACTUATE THERAPEUTICS, INC. announced that it will present preclinical data on elraglusib oral tablets at the ENA 2026 symposium.
Source:Nov 2, 2026, 13:00 UTC
The U.S. Patent and Trademark Office issued a notice of allowance for a patent covering ACTUATE THERAPEUTICS, INC.’ elraglusib oral tablets.
Source:Oct 30, 2026, 20:26 UTC
NASDAQ, INC. notified ACTUATE THERAPEUTICS, INC. that it was not in compliance with the minimum bid price requirement under Rule 5450(a)(1), with a compliance deadline of April 26, 2027.
Oct 28, 2026, 22:05 UTC
Actuate Therapeutics appointed Broadridge Corporate Issuer Solutions, LLC as warrant agent for the issuance, registration, transfer, exchange and exercise of warrants issued in the offering.
Oct 27, 2026, 12:00 UTC
Actuate Therapeutics announced pricing of an underwritten public offering of 30,985,900 common shares and warrants to purchase up to 15,492,950 shares at $0.71 per set of two shares and one warrant.
Source: